期刊文献+

补肾活血汤联合依降钙素治疗肾虚血瘀型骨质疏松症的临床研究 被引量:2

The clinical study on treating osteoporosis caused by kidney deficiency and blood stasis with the Bushen Huoxue decoction plus carbocalcitoni
下载PDF
导出
摘要 目的:观察补肾活血汤联合依降钙素治疗原发性骨质疏松症的安全性及临床疗效。方法:将符合病例标准患者96例采用随机分组法分为对照组和试验组,每组48例。两组治疗前由专业人员指导受试者建立一致且合理的饮食习惯及生活起居。对照组接受依降钙素治疗,肌肉注射,每周2次,每次1支;试验组在对照组的基础上接受依降钙素结合补肾活血汤治疗,水冲服,200 mL/袋,每次1袋,早、晚8时左右各1次,疗程为8周。对比评价治疗后腰椎骨密度(T值)、中医证候积分、骨代谢指标等各项指标。结果:试验组在提高腰椎骨密度、减轻疼痛、改善中医证候以及缓解腰椎活动障碍等方面的疗效比对照组显著,差异具有统计学意义(P<0.05);通过对安全性指标的评价,两组用药均安全,差异无统计学意义(P>0.05)。结论:补肾活血汤结合依降钙素比单纯运用依降钙素治疗原发性骨质疏松症疗效显著,能从症状上改善患者的病情,比如减轻腰背疼痛、减缓腰椎功能障碍,而且能通过抑制破骨细胞的活性、促进骨质向骨形成方向重塑进而提高患者的骨密度,从根本上治疗骨质疏松症,使患者的生活质量得到显著提升,且用药安全,疗效可靠,值得推广。 Objective:To observe the safety and clinical efficacy of the Bushen Huoxue decoction(补肾活血汤)with carbocalcitonin on primary osteoporosis.Methods:Ninety-six patients who met the case criteria were randomly divided into the control group and the experimental group,with 48 cases in each group.Before treatment,the two groups were given professionals guided the subjects to establish consistent and reasonable eating habits and living habits.The control group received calcitonin,Intramuscular injection,twice a week,once a time.And the experimental group received the Bushen Huoxue decoction more,water washing,200 mL per bag,1 sachet at a time,1 time at 8 a.m.and 1 time at 8 p.m.,for 8 weeks.The indexes such as lumbar bone mineral density(T value),TCM syndrome score and bone metabolism index after treatment were compared and evaluated.Results:The therapeutic effect in the experimental group was significantly higher than the control group in improving lumbar bone mineral density,alleviating pain,improving TCM syndrome and alleviating lumbar movement disorder(P<0.05).And by the evaluation of safety indicators,medication safety was found in both groups,with no significant difference(P>0.05).Conclusion:The Bushen Huoxue decoction with carbocalcitonin is more effective than carbocalcitonin alone in the treatment of primary osteoporosis.It can improve the patient's condition in terms of symptoms,such as relieving low back pain and lumbar dysfunction,and can increase the patient's bone mineral density by inhibiting the activity of osteoclasts and promoting bone remodeling to bone formation,fundamentally treat osteoporosis.The quality of life of patients has been significantly improved,and medication is safe and reliable,so it is worth popularizing to clinical application.
作者 赵敏 张鹏 温琦 ZHAO Min
出处 《中医临床研究》 2023年第22期51-55,共5页 Clinical Journal Of Chinese Medicine
关键词 补肾活血汤 依降钙素 肾虚血瘀型 原发性骨质疏松症 临床研究 The Bushen Huoxue decoction Carbocalcitonin Kidney deficiency and blood stasis Primary osteoporosis Clinical research
  • 相关文献

参考文献8

二级参考文献83

  • 1韩鹏勃,于继岗.加味身痛逐瘀汤对骨质疏松性疼痛患者的干预效应研究[J].辽宁中医杂志,2019,46(12):2571-2573. 被引量:9
  • 2Boyce BF, Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther,2007,9 Supp| 1 :S1.
  • 3Wright HL, McCarthy HS, Middleton J, et al. RANK, RANKL and osteoprotegerin in bone biology and disease. Curr Rev Musculoskelet Med ,2009,2( 1 ) :56-64.
  • 4LeeSH,Rho J, Jeong D, et al. v-ATPase V0 subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation. Nat Med ,2006,12 ( 12 ) : 1403-1409.
  • 5Perez-Amodio S, Beertsen W, Everts V. (Pre-)osteoclasts induce retraction of osteoblasts before their fusion to osteoclastsl. J Bone Miner Res,200d,19(10) :1722-17231.
  • 6Ehnert S, Baur J, Schmitt A, et al. TGF-[3 ( 1 ) As Possible Link between Loss of Bone Mineral Density and Chronic Inflammation. PLoS One,2010,5( 11 ) :e14073.
  • 7Jules J,Shi Z, Liu J, et al. Receptor Activator of NF- I kappa t B (RANK) Cytoplasmic IVVY535-538 Motif Plays an Essential Role in Tumor Necrosis Factor-{ alpha t ( TNF )-medlated Osteoclastogenesis. J Biol Chem,2010,285 (48) : 37427-37435.
  • 8Boyan BD,Schwartz Z, Lohmann CH. et al. Pretreatment of bone with osteoclasts affects phenotypic expression of osteoblast-like cells. J Orthop Res,2003,21 (4) :638-647.
  • 9Sanchez-Fernandez MA, Gallois A, Riedl T, et al. Osteoclasts control osteoblast chemotaxis via PDGF-BB/PDGF receptor beta signaling. PLoS One, 2008,3 ( 10 ) : e3537.
  • 10Kubota K, Sakikawa C, Katsumata M, et al. Platelet-derived growth factor BB secreted from osteoclasts acts as an osteoblastogenesis inhibitory factor. J Bone Miner Res, 2002,17 (2) :257-265.

共引文献1267

同被引文献48

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部